在BAG3中扩张性和多变性心肌病的双向风险调节器和修饰器变体
Joseph Park1,2,3,4, Michael G Levin2, David Zhang1,2,3
1Department of Genetics, Perelman School of Medicine, University of Pennsylvania, Philadelphia.
JAMA cardiology
|November 13, 2024
概括
BAG3 C151R变种调节扩张性心肌病 (DCM) 和多变性心肌病 (HCM) 风险,作为DCM的保护因素,特别是当TTN变种存在时. 这一发现增强了对DCM的理解.
科学领域:
- 心血管遗传学 心血管遗传学
- 分子心脏病学分子心脏病学
- 遗传流行病学遗传流行病学
背景情况:
- 遗传性扩张性心肌病 (DCM) 呈现的透率降低和可变的表达性,其潜在的遗传因素基本上未知.
- BAG3遗传变异与DCM和高伤心肌病 (HCM) 都有关,这表明BAG3含有DCM的潜在修饰变异.
研究的目的:
- 调查与BAG3编码变异相关的临床特征和疾病.
- 确定影响DCM透度和表达力的基因修饰剂.
主要方法:
- 使用宾夕法尼亚大学医学生物库 (PMBB) 进行的横截面研究,与与电子健康记录 (EHR) 数据相关的全外体序列 (WES) 进行了连接.
- 对BAG3编码变体与临床诊断,心声学特征和纵向结果的关联分析.
- 在BioVU,英国生物银行,MyCode和DCM精密医学研究中的复制研究.
主要成果:
- 常见的BAG3 C151R变异与DCM风险降低 (OR,0.85) 和HCM风险增加 (OR,1.59) 相关,在复制队列中得到证实.
- 携带C151R的携带者表现出更好的纵向结果,包括延迟死亡年龄和减少心脏移植率.
- 在具有截断TTN变异的个体中,C151R与DCM (OR,0.42) 和心力衰竭 (OR,0.27) 的风险降低有关.
结论:
- BAG3 C151R作为DCM-HCM频谱上的双向风险调节器,是TTN介导DCM中的重要基因修饰剂.
- 这项研究扩大了对DCM病因和透性的理解,突出了BAG3 C151R在DCM可变表达性中的作用.
- 需要对BAG3 C151R机制和其他DCM中的基因修饰剂进行进一步的研究.
相关概念视频
Mitral Regurgitation I: Introduction
4
Mitral regurgitation is characterized by the backward circulation of blood from the left ventricle to the left atrium during systole, a phase of the cardiac cycle when the heart contracts and pumps blood out of the chambers. This abnormal flow occurs primarily due to the dysfunction of the mitral valve or its supporting structures, which include the mitral leaflets, chordae tendineae, annulus, and papillary muscles.Etiology and Mechanisms:Primary Mitral Regurgitation: This type arises from...
4
Mitral Valve Prolapse I: Introduction
4
IntroductionThe mitral valve, one of the heart's four valves, regulates blood flow. These valves have flaps that open and close to direct blood properly through the heart and body. During each heartbeat, the flaps open for blood to pass through and seal shut to prevent backflow. Specifically, the mitral valve opens to allow blood flow from the heart's upper left chamber to the lower left chamber. It then closes securely as the lower left chamber contracts to pump blood to the body, preventing...
4
Mitral Regurgitation III: Medical Management
4
Mitral regurgitation (MR) is characterized by retrograde blood circulation from the left ventricle into the left atrium due to inadequate mitral valve closure. The severity of the condition, symptoms, and underlying cause determine treatment strategies.Monitoring and Pharmacological TreatmentPatients with mild to moderate MR typically do not need immediate intervention but regular monitoring to assess progression and guide treatment. Patients with mild MR should have an echocardiogram every 3-5...
4
Genetic Lingo
101.2K
Overview
101.2K
Mitral Stenosis I: Introduction
2
Mitral Valve Stenosis (MVS) is a heart condition where the mitral valve narrows, impeding blood circulation from the left atrium to the left ventricle. The etiology and pathophysiology of this condition are multifaceted, leading to a cascade of cardiovascular complications.Causes of Mitral Valve StenosisRheumatic Heart Disease: It is the main cause of mitral valve stenosis, particularly in developing nations. This condition arises from rheumatic fever, an inflammatory illness resulting from...
2
Mitral Valve Prolapse III: Nursing Management
5
The nursing management of Mitral Valve Prolapse, or MVP, centers around patient education, symptom monitoring, and lifestyle modifications.Patient Education on MVP Diagnosis and Heredity: Nurses should provide comprehensive education about MVP, a condition where the mitral valve does not close appropriately during heartbeats. This education often includes the condition's pathophysiology, symptoms, and potential complications, like arrhythmias or mitral regurgitation. Though not fully...
5


